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Background and purpose: Prenatal patency of ductus arteriosus is maintained by prostaglandin (PG) E2, possibly along with
nitric oxide (NO) and carbon monoxide (CO), and cyclooxygenase (COX) deletion upregulates NO. Here, we have examined
enzyme source and action of NO for ductus patency and whether NO and CO are upregulated by deletion of, respectively,
heme oxygenase 2 (HO-2) and COX1 or COX2.
Experimental approach: Experiments were performed in vitro and in vivo with wild-type and gene-deleted, near-term mouse
fetuses.
Key results: NG-nitro-L-arginine methyl ester (L-NAME) contracted the isolated ductus and its effect was reduced by eNOS,
but not iNOS, deletion. L-NAME contraction was not modified by HO-2 deletion. Zinc protoporphyrin (ZnPP) also contracted
the ductus, an action unaffected by deletion of either COX isoform. Bradykinin (BK) relaxed indomethacin-contracted ductus
similarly in wild-type and eNOS/ or iNOS/. BK relaxation was suppressed by either L-NAME or ZnPP. However, it
reappeared with combined L-NAME and ZnPP to subside again with Kþ increase or Kþ channel inhibition. In vivo, the ductus
was patent in wild-type and NOS-deleted fetuses. Likewise, no genotype–related difference was noted in postnatal closure.
Conclusions and implications: NO, formed mainly via eNOS, regulates ductal tone. NO and CO cooperatively mediate BK-
induced relaxation in the absence of PGE2. However, in the absence of PGE2, NO and CO, BK induces a relaxant substance
behaving as an endothelium-derived hyperpolarizing factor. Ductus patency is, therefore, sustained by a cohort of agents with
PGE2 and NO being preferentially coupled for reciprocal compensation.
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Introduction
Prenatal patency of the ductus arteriosus is an active state
of the vessel, being sustained by several agents. Although the
cyclooxygenase (COX) pathway is assigned a prime role,
with prostaglandin (PG) E2 rather than PGI2 as the major
effector, nitric oxide (NO) and carbon monoxide (CO) are
viewed as additional effectors acquiring prominence under
certain conditions (Smith, 1998; Narumiya et al., 1999;
Kobayashi and Narumiya, 2002). In fact, NO function is
upregulated upon deletion of either COX in the PGE2
synthetic pathway (Baragatti et al., 2003), as expected from
a complementary arrangement between the two systems
(Seidner et al., 2001; Takizawa et al., 2001). This cooperative
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interaction may also occur during fetal development as, in
the preterm ductus, NO is more effective than PGE2, whereas
the opposite is noted at term (Momma and Toyono, 1999;
Takizawa et al., 2001; Richard et al., 2004). It is an open
question whether a reciprocal compensation may also exist
between NO and CO, on the one hand, and between PGE2
and CO, on the other. Furthermore, there is no agreement on
the expression of individual nitric oxide synthase (NOS)
enzymes in the vessel. In a previous study in the mouse
(Baragatti et al., 2003), we detected only the endothelial
isoform (endothelial nitric oxide synthase (eNOS)), and our
finding accords with another report in the same species
proving the presence of eNOS with minimal amounts of the
inducible nitric oxide synthase (iNOS) and neural nitric
oxide synthase (nNOS) isoforms (Richard et al., 2004). The
lamb ductus, however, may present a full complement of
NOS isozymes, although eNOS still maintains its pre-
eminence in vasoregulation, and nNOS is assigned an
additional role in morphogenesis (Clyman et al., 1998;
Mason et al., 1999; Rairigh et al., 2000).
The objective of this study was twofold, using a combina-
tion of gene deletions and pharmacological manipulations
in the mouse. Our primary aim was to assess the actual
importance of eNOS-derived NO for the regulation of basal
tone of the ductus and the response of the vessel to the
endothelium-dependent dilator bradykinin. Bradykinin is
a known activator of NO and has been implicated in the
control of the perinatal circulation (see Coceani et al., 1994;
Bateson et al., 1999). Second, we wished to ascertain whether
NO activity in the ductus increases following removal of the
CO-forming enzyme (specifically, heme oxygenase 2 (HO-2))
and, as a corollary, whether CO function is upregulated upon
COX removal. An answer to the latter questions would
indicate whether or not the functional linkage between NO
and PGE2, as reported earlier (Baragatti et al., 2003), has a
unique character. An advantage in using the mouse ductus is
that it combines the pre-eminence of eNOS (Baragatti et al.,
2003; Richard et al., 2004) with the absence of vasa vasorum
(Richard et al., 2004), so that the luminal endothelium
becomes the main, if not the only, source of NO. Such
arrangement eliminates a potential complication in the
interpretation of findings, as may occur with the lamb
(Clyman et al., 1998).
Methods
Experiments were carried out in B6/129 mice or in B6/129
mice backcrossed onto the C57BL/6 strain (NOS mutants)
with the following genotypes: eNOS/ (litter size, 2–10;
mean, 7) (line of Leuwerke et al. (2002) from the original
stock of Shesely et al. (1996)); iNOS/ (litter size, 4–10;
mean, 6; Laubach et al., 1995); COX1/ (litter size, 2–7;
mean, 5) and COX2/ (litter size, 4–10; mean, 8; courtesy
of Dr L Ballou; see Morham et al., 1995); HO-2/ (litter size,
4–10; mean, 7) (Regan et al., 2004).
HO-1 was not studied in view of the difficulties in breeding
a null mutant and the knowledge that it is less expressed
than HO-2 in the ductus (Coceani et al., 1997). Wild-type
(WT) C57BL/6 mice (litter size, 1–12; mean, 7) served as a
control after having verified that they behave as the WT
B6/129 mice. In all cases, genotype was confirmed in tail
specimens by polymerase chain reaction (PCR). Animals
were housed in temperature- and humidity-controlled
quarters with constant 12:12-h light–dark cycles and were
given food and water ad libitum. Surgical procedures and
experimental protocols were approved by the Animal Care
Committee of the Ministry of health.
In vitro studies
Term fetal mice, both WT and gene-deleted (gestational age,
19 days), were delivered by Caesarean section under
halothane anaesthesia and were killed by cervical disloca-
tion. Body weight varied between 0.9 and 1.5 g, and only one
fetus was used in each experiment. The procedure for
dissection of the ductus arteriosus, normalization of internal
circumference and mechanical record has been described
previously (Coceani et al., 1999). In brief, the animal was
secured with its left-side up in a dissection chamber
containing ice-cold Krebs solution gassed with 5% CO2
in N2. Through a thoracotomy, the ductus was exposed,
separated from the adjoining large blood vessels and then
suspended onto 25-mm tungsten wires (Cooner wire, Chats-
worth, CA, USA) inside an organ bath. In some experiments,
the ductus was prepared without the endothelium. For this
purpose, a cat whisker of suitable size, its surface coarse from
polishing with fine-grain sandpaper (600 grit), was passed
through the lumen before isolating the vessel. The procedure
for preparing endothelium-denuded vessels has been de-
scribed elsewhere (Wang et al., 1994), and successful removal
was confirmed by scanning electron microscopy (see Adeag-
bo et al., 1990). The fluid of the bath was gassed with gas
mixtures containing 2.5 or 12.5% O2 to mimic, respectively,
the fetal and the neonatal condition. The same mixtures
were flushed through a hood covering the bath. Preparations
were then equilibrated (about 60 min at 371C) with a
minimal stretch being applied (all values in mN mm1)
(WT, 0.0570.003 (n¼61); eNOS/, 0.0770.005 (n¼27);
iNOS, 0.0470.0009 (n¼14); COX1/, 0.0770.007 (n¼7);
COX2/, 0.0670.008 (n¼7); HO-2/, 0.0870.01 (n¼ 10))
and the attendant internal circumference (C0) with the
related resting dimension (Table 1) served as a reference for
choosing the appropriate load. Afterwards, tension was applied
to attain an operating circumference (i.e. C50) coinciding with
the condition in vivo (WT, 0.4770.004 (n¼61); eNOS/,
0.4570.006 (n¼27); iNOS, 0.5270.009 (n¼ 14); COX1/,
0.4470.005 (n¼7); COX2/, 0.4570.008 (n¼7); HO-2/,
0.4570.008 (n¼10); all values in mN mm1), and the actual
experiment was started following a second, 60- to 100-min
period of equilibration.
Congruent with its objectives (see above), the study
composed of two main protocols, each with distinct lines
of investigation. Unless otherwise specified, experiments
were carried out at 2.5% O2. In protocol 1 (n¼92), NG-nitro-
L-arginine methyl ester (L-NAME) (100 mM) action was
assessed in the WT vs eNOS/ and iNOS/ ductus at
rest. In addition, the effect of isoform-specific NOS deletions
and selected inhibitors was ascertained on the relaxation
of the ductus to bradykinin. Bradykinin was tested in
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cumulative concentrations (0.01 nM–10mM) on preparations
precontracted with indomethacin (2.8 mM), and specificity of
responses was confirmed through endothelium removal or
exposure to excess Kþ (55 mM). Indomethacin was chosen
for pre-contraction to avoid any confounding influence
from bradykinin-induced PGE2 formation (Bateson et al.,
1999). Inhibitors included L-NAME and zinc protoporphyrin
(ZnPP) (10 mM), being used individually or together, and
the combination of 1-[(2-chlorophenyl)diphenylmethyl]-1
H-pyrazole (TRAM-34) (1 mM)/apamin (0.2 mM) for the identi-
fication of any endothelium-derived hyperpolarizing factor
(EDHF)-induced relaxation. A single concentration–response
curve for bradykinin was obtained in every preparation to
avoid any tachyphylaxis, and a maximal concentration of
sodium nitroprusside (SNP) (100 mM) was applied at the end
of the experiment to confirm muscle viability and functional
integrity of the guanylyl cyclase therein. Preservation of
endothelial function could not to be verified at the
beginning of the experiment since bradykinin is the only
suitable agent for tests on the ductus (Bodach et al., 1980;
Coceani et al., 1994). However, no evidence was ever
obtained, in this as in other studies (Coceani et al., 1999),
of inadvertent damage to the endothelium while setting up
the preparation. SNP was also tested separately over a full
range of concentrations (0.1 nM–100 mM) to obtain a
reference for the bradykinin-induced relaxation. The throm-
boxane A2 (TX)A2 analogue (0.1 mM) provided instead a
reference for contractile responses.
In protocol 2 (n¼34), L-NAME was tested on WT and HO-
2/ preparations after having confirmed with ZnPP that
this HO isoform contributes to tone regulation. Likewise,
ZnPP action was assessed on the basal tone of the WT vs
COX1/ and COX2/ ductus at both 2.5 and 12.5% O2.
As a separate control, ZnPP was also tested on the eNOS/
vessel to verify whether NO facilitates CO by affecting its
formation (Motterlini et al., 2002) or action (Barkoudah
et al., 2004). In all cases, only one test procedure was
employed with each vessel.
In vivo studies
Experiments were carried out in fetuses (gestational age, 19
days) or newborns (3 and 12 h) depending on the protocol.
In the former case, animals (WT and NOS-deleted) were
delivered by Caesarean section under halothane anaesthesia,
whereas in the latter they were used at the stated intervals
after vaginal delivery. Time zero (i.e. the time at which
delivery was completed) was assessed for each animal in the
litter. Separate experiments were performed in eNOS/
fetuses whose mother had been treated for 3 days with
indomethacin (2 mg kg1 per os daily). The intent in the
latter case was to verify the impact of PGE2 suppression on
ductus patency when NO formation is impaired. Throughout
the survival period, newborns were kept with the mother.
All animals were killed by cervical dislocation.
Changes in ductus calibre through the transition from
the pre- to the postnatal condition were assessed by fixing
the vessel in situ with the whole-body freezing technique
(Ho¨rnblad and Larsson, 1967; Coceani et al., 1999). Briefly,
animals were placed with their right-side up in a Petri dish
and were covered with an embedding medium (Tissue-Tek
optimum cutting temperature compound; Sakura Finetek,
Torrance, CA, USA). The dish with the animal was then
wrapped with aluminium foil and immersed in liquid N2.
Once frozen, specimens were stored at 201C for further
work-up. To prepare a block of tissue with the ductus, the
carcass was freed of its embedding in the frozen state. With a
razor blade, soft tissues covering the dorsum were removed,
making certain that the exposed surface would be parallel
to the underlying descending aorta and hence perpendicular
to the ductus. Serial, transversal sections (5 mm thick),
progressing from this cut through the whole length of
the vessel, were obtained on a Zeiss freezing microtome
(model HM500 OM, Walldorf, Germany) and were stained
with 1% methylene blue. Care was taken to collect a
complete series of ductus sections. Afterwards, each section
was photographed with a charge-coupled device solid-state
camera (COHU, San Diego, CA, USA) and lumen area of
the ductus was measured with a MCID-M4 program (Brock
University, St Catharines, Canada). Both maximal and
minimal values of this area were retrieved from each series
for computation.
Total RNA preparation and quantitative real-time-PCR
Ductuses were collected from fetuses (gestational age, 19
days; WT and eNOS/) whose mother had been treated
with indomethacin (see above) and were pooled in one
group for each genotype (50 and 30 specimens/group,
respectively, for WT and eNOS/). Indomethacin pretreat-
ment, which is as effective as COX deletion in promoting NO
function in the ductus (Baragatti et al., 2003; D Sodini,
unpublished data), was used to maximize any upregulation
of iNOS and nNOS upon eNOS deletion. Coincidentally, this
approach reproduced the protocol for testing bradykinin
in vitro (see above). RNA was isolated as described earlier
(Baragatti et al., 2003), and its yield was measured spectro-
photometrically.
DNAse I (Roche, IN USA)-treated total RNA (2.4 mg for each
group) was reverse-transcribed with 1 U of Thermoscript RT
Table 1 Resting dimension of isolated ductus arteriosus from WT and
gene-deleted term fetal mice
Genotype Internal diameter Vessel lengtha Wall thickness
Short side Long side
WT (n¼61) 13971 53278 54578 1970.3
eNOS/ (n¼27) 13271* 545710 55879 2070.4
iNOS/ (n¼14) 15272** 553710 569710 1970.7
COX1/ (n¼7) 13071 501734 510734 2170.7
COX2/ (n¼7) 13172 460714 473713 1870.4
HO-2/ (n¼10) 13372 511729 523728 1970.8
Abbreviations: ANOVA, analysis of variance; COX, cyclooxyygenase; eNOS,
endothelial nitric oxide synthase; HO, heme oxygenase; iNOS, inducible nitric
oxide synthase; WT, wild type.
Values (mm) are mean7s.e.m.
aVessel length of the ductus arteriosus is uneven because of its insertion into
aorta at an angle. Short side was taken for normalization of internal
circumference and calculation of tension output (see in vitro studies).
*Po0.01, **Po0.001 vs WT (ANOVA with Bonferroni post hoc test). Note
that the internal diameter of the ductus was smaller in eNOS/ than WT,
whereas the reverse occurred with iNOS/.
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(Invitrogen, Carlsbad, CA, USA) in the presence of random
hexanucleotide primers, according to the manufacturer’s
instructions. Quantitative real-time (QRT)-PCR reactions (40
cycles) were performed on an ABI Prism 7700 instrument
(Applied Biosystems, Foster City, CA, USA) using the TaqMan
Universal PCR Master Mix (Applied Biosystems). Primer
sequences for mouse iNOS, nNOS and cyclophilin B (internal
standard) were obtained from an online library (Applied
Biosystems). Gene expression was quantified in triplicate for
each of the two groups by the comparative cycle-threshold
method and was expressed in arbitrary units against
reference cyclophilin.
Solutions and drugs
The Krebs medium had the following composition (mM):
NaCl 118, KCl 4.7, CaCl2 2.5, KH2PO4 1, MgSO4 0.9, dextrose
11.1 and NaHCO3 25. Potassium–Krebs solution (20 and
55 mM) was prepared by substituting NaCl with an equimolar
amount of KCl. Depending on the stage of the experiment
(see above), the solution was bubbled with gas mixtures
containing either no O2 or O2 in one of two concentrations
(2.5 and 12.5%) plus 5% CO2 and balance N2. PO2 was
measured with a Chiron gas analyzer (model 248, Halstead,
UK) and was 0.9870.001, 2.1370.007 and 6.6770.04 kPa
(pH 7.4170.004) when gas mixtures had 0, 2.5 and 12.5%
O2, respectively.
The following compounds were used: bradykinin acetate
(Sigma, St Louis, MO, USA); the NOS inhibitor, L-NAME
(Sigma); the HO inhibitor, ZnPP (Porphyrin Products,
Carnforth, UK); the dual COX1/COX2 inhibitor, indometha-
cin (Sigma); a recently developed inhibitor of intermediate-
conductance Ca2þ -activated Kþ channels, TRAM-34; cour-
tesy of Dr H Wulff) which, unlike other compounds in this
category, has no effect on cytochrome P450-based reactions
(Wulff et al., 2000); the inhibitor of small-conductance
Ca2þ -activated Kþ channels, apamin (Sigma); the TXA2
analogue 9,11-epithio-11, 12-methano-TXA2 (ONO-11113,
courtesy of ONO Pharmaceutical, Osaka, Japan); and SNP
(Sigma). Concentrations of the inhibitors were derived from
the literature with the aim of combining efficacy with
selectivity. In particular, at the stated concentrations, the
combination TRAM-34/apamin is able to reverse fully any
EDHF-mediated vasodilatation (Eichler et al., 2003). In
addition, ZnPP exerts a specific effect on the HO enzyme
complex in the ductus (Coceani et al., 1997).
ONO-11113 was dissolved in distilled ethanol (5 mg ml1),
and aliquots (stored at 701C) were diluted with Tris buffer
(pH 7.4). Indomethacin and TRAM-34 were also dissolved in
ethanol (10 and 1 mg ml1, respectively) before preparation
of the final solution in the Krebs medium. Likewise, ZnPP
was first prepared as a stock solution in 0.1 M NaOH (1 mM)
on the day of the experiment. Ethanol in the fluid bathing
isolated ductus preparations did not exceed 0.03% (TRAM-
34), 0.01% (indomethacin) or 0.001% (ONO-11113). Other
substances dissolved readily in saline or Krebs medium.
Solutions of certain compounds (SNP, ZnPP) were protected
from light.
Concentrations of compounds are given in molar units
and refer to their final value in the bath. Vehicle alone,
without or with ethanol (see above), had no effect on vessel
tone.
Analysis of data
Baseline contractile tension, which varied with the prepara-
tion (see Results), refers to the net active tension (i.e. total
tension minus applied tension) developed by the prepara-
tion before any treatment. Responses to the constrictors were
measured by the rise in tension over baseline and were
expressed in absolute values. Relaxant responses were given
as reversal of tension (percent or absolute values) in the
indomethacin-precontracted vessel.
Data are expressed as the mean7s.e.m. Comparisons
were made using a Student’s t-test or analysis of variance
(ANOVA), followed by the Bonferroni test. Differences are
considered significant for Po0.05.
Results
mRNA analysis
Although previous work has failed to demonstrate mRNA
for both iNOS and nNOS in the ductus of the WT mouse
(Baragatti et al., 2003), a further analysis was performed here
to verify whether either isoform becomes detectable upon
eNOS deletion. However, even with a 40-cycle amplification,
QRT-PCR showed barely detectable iNOS and nNOS signals
(detection at 38 cycles), with values for the eNOS/mutant
straddling those of the WT.
In vitro studies
The isolated ductus arteriosus was smaller in eNOS/ than
in WT, whereas the opposite was seen with iNOS/
(Table 1). All preparations, whether WT or gene-deleted,
developed a variable degree of tension (0.16–0.47 mN mm1)
during equilibration. Coincidentally, as reported elsewhere
(Coceani et al., 1999; Baragatti et al., 2003), the baseline
presented, singly or in combination, slow contractions of
variable magnitude (0.1–0.8 mN mm1 and exceptionally
higher, maximum 1.1 mN mm1) and rapid discharges of
low amplitude. The incidence of such activity was lower in
the iNOS mutant (15% of preparations) than in other
genotypes (70% of preparations). Indomethacin (2.8 mM)
contracted the ductus similarly in the various of genotypes
(Table 2). Likewise, minor and mostly insignificant varia-
tions were noted in the elevated tone before bradykinin tests
when, in examining the mode of action of the compound
(see below), indomethacin was variably combined with other
inhibitors and excess potassium (Table 2). The reference
TXA2 analogue, ONO-11113 (0.1 mM), was only slightly
more potent than indomethacin (WT, 1.2170.07 mN mm1,
n¼17; eNOS/, 1.1270.08 mN mm1, n¼ 11), indicating
that the baseline for bradykinin-induced relaxation was close
to the maximal contractile capacity of the vessel.
NO function. L-NAME (100 mM) contracted the ductus from
the WT mouse (Figure 1). The contraction started after some
delay (8–16 min), progressed gradually to a peak (maximum
in 80–90 min) and was sustained thereafter. A similar
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contraction was observed in the eNOS mutant, but the
response was smaller and often not sustained (Figure 1a).
Conversely, the iNOS/ ductus responded as the WT to
L-NAME, thus pointing against a significant role of this
isoform in basal vasoregulation (Figure 1a).
Bradykinin relaxed dose-dependently the WT ductus
precontracted with indomethacin. As shown in Figure 1b,
threshold was around 10 pM and maximum at 10–100 nM
(3974% maximum reversal) compared with an SNP range
from 10 nM onwards (100712% max reversal). Coinciden-
tally, relaxant responses were often preceded by an abrupt
and rapidly reversible contraction of small magnitude
(maximum about 0.1 mN mm1). No bradykinin-induced
relaxation was found with the endothelium-denuded ductus
and, in fact, the relaxation was replaced in certain cases by a
marginal contraction (0.0870.06 mN mm1 at 10 mM, n¼4).
A similar change from a relaxation to a modest contraction
was seen when bradykinin was tested with excess potassium
(0.0570.03 mN mm1 at 55 mM, n¼3). Conversely, SNP
relaxation remained unabated in the absence of the
endothelium (131713% reversal at 100 mM, n¼ 4).
eNOS and iNOS deletion caused no significant change in
the bradykinin-induced relaxation (Figure 1c), whereas the
same relaxation in the WT was suppressed by either L-NAME
or ZnPP (Figure 2a). This coincidence between L-NAME and
ZnPP has already been found in the lamb ductus (Coceani
et al., 1997) and implies that NO and CO act sequentially in
mediating the bradykinin-induced relaxation. Nevertheless,
when L-NAME and ZnPP were combined, the relaxation was
restored over the entire concentration range and, in fact, was
enhanced compared to the original response (5374 vs
3974% maximum reversal; P¼0.001, ANOVA) (Figure 2a).
An even greater response (9177% maximum reversal;
Po0.001, ANOVA) was seen when testing bradykinin in the
ZnPP-treated, eNOS mutant (Figure 2d). This restored
relaxation progressively abated with a stepwise rise of
potassium concentration (Figure 2b) and also subsided
with TRAM-34 plus apamin treatment (Figure 2c and d).
Table 2 Isolated ductus arteriosus from term fetal mice: wall tension before bradykinin-induced relaxation
Condition Genotype
WT eNOS/ iNOS/
Indomethacin 0.8870.11 (10) 1.0570.08 (6) 0.7170.11 (6)
Indomethacinþ L-NAME 0.9970.06 (5) — —
IndomethacinþZnPP 0.7970.09 (6) 0.9070.12 (4) —
Indomethacinþ L-NAMEþZnPP 1.2070.09 (4) — —
Indomethacinþ L-NAMEþZnPPþKþ 20 mM 0.7670.09 (4) — —
Indomethacinþ L-NAMEþZnPPþKþ 55 mM 1.070.18 (4) — —
Indomethacinþ L-NAMEþZnPP þ TRAM-34þ apamin 1.2170.18 (4) — —
Indomethacinþ TRAM-34þ apamin — 0.5270.05 (7)* —
IndomethacinþZnPPþTRAM-34þ apamin — 0.6170.03 (3)** —
Abbreviations: ANOVA, analysis of variance; eNOS, endothelial nitric oxide synthase; iNOS, inducible nitric oxide synthase; L-NAME, NG-nitro-L-arginine methyl
ester, TRAM-34, 1-[(2-chlorophenyl)diphenylmethyl]-1H-pyrazole; WT, wild-type; ZnPP, zinc protoporphyrin.
Values (mN mm1) are mean7s.e.m. and apply to the steady tension of the preparation. Number of experiments in parentheses. Ductus preparations from WT
and NOS-deleted animals were treated with indomethacin alone or in combination with excess potassium and the required inhibitors in various combinations (for
details, see text).
*Po0.01, **Po0.05 vs indomethacin alone in the same genotype (ANOVA with Bonferroni post hoc test). Note that differences in the indomethacin response
among genotypes are not significant.
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Figure 1 Isolated ductus arteriosus from fetal mouse. (a) Compar-
ison of contractile responses to L-NAME (100mM) in WT vs NOS- and
HO-2-deleted preparations (n, above columns). Baseline wall tension
(mN mm1) before treatment was as follows: WT, 0.0470.02;
eNOS/, 0.2370.06; iNOS/, 0.2870.06; HO-2/, 0.0270.02.
A significant difference (see asterisk) was found between WT and
eNOS/ (Po0.05; ANOVA). eNOS/ also differed from WT in
presenting a non-sustained L-NAME contraction in some cases (n¼2).
(b and c) Concentration–response curves to bradykinin, respectively, in
WT (n¼5 for both groups) and NOS-deleted (n¼6 for both groups)
preparations precontracted with indomethacin (2.8mM). Wall tension
before bradykinin was as follows: (b) WT, 1.0470.17 (before SNP,
0.7370.11); and (c) eNOS/, 1.0570.08; iNOS/, 0.7170.11.
Progression of concentration-dependent changes is significant with each
condition (Po0.001), whereas bradykinin relaxation is not different
among genotypes (ANOVA in all cases). Where necessary, points have
been offset to improve visibility, and any missing s.e. bar is within the size
of the symbol.
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Conversely, in the absence of ZnPP, the same TRAM-34/
apamin combination failed to modify the bradykinin-
induced relaxation of the eNOS/ ductus in four of seven
experiments (6478% maximum reversal). The remaining
three experiments, however, showed complete suppression
of the response.
NOS/HO and HO/COX interactions in tone regulation. It was
first confirmed that HO-2, with its CO product, sustains
ductus relaxation by showing a weaker ZnPP contraction
after deletion of this particular gene (Figure 3). This
contraction, whether full-fledged or curtailed, developed
gradually in time (maximum in 90–160 and 30–140 min
in WT and HO-2/, respectively) and was maintained after
reaching its peak. However, at variance with the COX-
deleted animal (Baragatti et al., 2003), the HO-2-deleted
animal did not present any NO upregulation. As shown in
Figure 1a, L-NAME was equally effective with and without
the HO-2 gene. Likewise, the ZnPP contraction was not
modified by deletion of either COX at both 2.5 and 12.5% O2
(Figure 3). Conversely, no response to ZnPP was seen in the
eNOS mutant, and baseline tension of the ductus remained
virtually unchanged throughout treatment (control:
0.170.08 mN mm1, ZnPP: 0.1970.04 mN mm1; n¼3).
In vivo studies
The ductus was patent in all fetuses, regardless of genotype,
with a wider lumen in the eNOS mutant (Figure 4). The same
trend for a larger ductus, albeit without reaching signifi-
cance, was also noted in the iNOS mutant. Postnatally, both
WT- and NOS-deleted animals constricted their ductus
rapidly so that the lumen was consistently reduced to a
fraction of the prenatal value by 3 h and was virtually absent
at 12 h (Figure 4). During this period, narrowing was either
even over the entire length of the vessel or was more
prominent in its central portion.
Pretreatment of the eNOS/ fetus with chronic indo-
methacin did not cause marked constriction or closure of
the ductus. In fact, the vessel lumen, which is paradoxically
enlarged in this mutant (Figure 4), was reduced after
indomethacin treatment to a value matching that of the
untreated WT (max area: 126 523717 139 mm2; min area:
92 712714 029 mm2; n¼5; Po0.01 and NS vs untreated
eNOS / and WT, respectively; ANOVA).
Discussion
The present study shows that NO, originating within the
endothelium, exerts a tonic relaxant effect on the fetal
ductus. This finding accords with our earlier results in the
isolated lamb ductus (Coceani et al., 1994) as well as with
in vivo experiments (Bustamante et al., 1996; Momma and
Toyono, 1999; Takizawa et al., 2001; Richard et al., 2004),
thus yielding further evidence against reports negating any
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Figure 2 Concentration–response curves to bradykinin in the
isolated mouse ductus arteriosus. Vessels were pretreated with
indomethacin (2.8 mM) plus other inhibitors and excess potassium in
various combinations. (a) WT, L-NAME (100mM, n¼5), ZnPP (10mM,
n¼6), L-NAME/Znpp (n¼4) (b) WT, L-NAME/ZnPP alone (n¼4)
and with Kþ 20 mM (n¼5) or Kþ 55 mM (n¼4). (c) WT, L-NAME/
ZnPP alone (n¼4) and with TRAM-34 (1 mM)/apamin (0.2mM)
(n¼4). (d) eNOS/, ZnPP alone (n¼4) and with TRAM-34/
apamin (n¼3). Bradykinin curve during treatment with L-NAME/
ZnPP is the same as in (a), (b) and (c). Values of wall tension
(mN mm1) before bradykinin under the various conditions are given
in Table 2. Progression of concentration-dependent responses to
bradykinin is significant for L-NAME-/ZnPP-treated WT preparations,
in the absence and presence of Kþ 20 mM and for ZnPP-treated
eNOS/ preparations (Po0.001, ANOVA). In each panel, brady-
kinin curves marked with an asterisk differ from the other curves
(P¼0.001, or better). Where necessary, points have been offset to
improve visibility and any missing s.e. bar is within the size of the
symbol.
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Figure 3 Isolated ductus arteriosus from fetal mouse. Comparison
of contractile responses to ZnPP (10mM) in WT vs HO-2- and COX-
deleted preparations. Note that results with COX mutants were the
same at 12.5% O2 (n¼3 for each genotype). Wall tension
(mN mm1) before treatment was as follows: WT, 0.2870.07; HO-
2/, 0.1570.09; COX1/, 0.3170.07; COX2/, 0.1670.04.
For each group, the number of experiments is given above the
columns, and a significant difference (Po0.01; ANOVA) between
WT and HO-2/ preparations is indicated with an asterisk.
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such control (Clyman et al., 1998; Bateson et al., 1999). NO
was formed via eNOS but, as the L-NAME contraction was
only partially curtailed in the eNOS mutant (see Figure 1a), a
contribution from other NOS isoforms must be considered in
spite of their modest mRNA expression. An explanation for
this discrepancy could be that either, or both, isoforms are
located at some discrete, yet critical, site in the vessel.
Consistent with an accessory role of iNOS/nNOS is also the
observation that bradykinin-induced relaxation was, on the
one hand, suppressed in the L-NAME-treated, WT ductus
and, on the other, was preserved in the untreated vessel
lacking eNOS. However, despite its identification with a
natural relaxant, eNOS-derived NO is not critical for ductus
patency. eNOS deletion does not cause any narrowing of the
vessel in vivo and, on the contrary, manifests itself with a
paradoxical change in the opposite direction. Concomi-
tantly with NO, the ductus may generate CO and this
possibility supporting a normal function for the compound
distinguishes the mouse from the lamb where ZnPP is
without effect on the resting tone (Coceani et al., 1997).
Indeed, our finding in the mouse that ZnPP and indometha-
cin contract the ductus to a similar degree implies an
equivalent relaxant function for CO and PGE2. Nevertheless,
the two compounds differ in that deletion of CO-forming
HO-2, unlike deletion of PGE2-forming COXs (Baragatti
et al., 2003), is not followed by a compensatory upregulation
of the NO system. Hence, the concept is strengthened of a
special linkage being in place between PGE2 and NO for the
control of ductal tone. CO, on the other hand, appeared
to share with NO an intermediary role in the bradykinin-
induced relaxation, with the two agents being coupled in a
cooperative sequence (see Coceani et al., 1997). Significantly,
when both NO and CO were suppressed along with PGE2,
another relaxing agent became evident with the properties
of EDHF. Based on this premise, our discussion will address
two main issues: the nature of the interaction between NO
and CO in ductus regulation at rest and in response to
bradykinin, and the significance of EDHF for maintenance of
ductus patency.
The nature of the interaction between NO and CO is
intriguing and is best examined by treating it separately in
the resting vessel and during the bradykinin-induced relaxa-
tion. In the former case, NO, deriving primarily from eNOS,
exerts a direct effect on ductal muscle. CO is unlikely to
participate in its action, considering that the L-NAME
contraction does not differ between WT and HO-2-deleted
preparations (see Figure 1a). Conversely, ZnPP contraction is
curtailed in the eNOS mutant, implying a crucial role of NO
in CO-mediated ductal tone. Both agents, on the other hand,
mediate the bradykinin-induced relaxation since suppres-
sion of either NO or CO results in its loss. The actual
mechanism for this interdependence cannot be assessed with
our data, but it may be inferred from the literature. Indeed,
a cooperative sequence being triggered by bradykinin, with
NO promoting the synthesis of CO, is feasible in view of the
extensive evidence supporting this particular function for
NO itself and any reactive nitrogen species (Motterlini et al.,
2002). Alternatively, NO may be permissive for CO in line
with evidence from elsewhere in the perinatal vasculature
(Barkoudah et al., 2004). Significantly, in support of the latter
scheme, we have found that ductus relaxation to CO
decreases upon L-NAME treatment (Coceani et al., 1996).
These two possibilities are not mutually exclusive and, in
addition, can account for the NO dependence of the CO
relaxation in the ductus at rest.
Whatever the nature of the synergy between NO and CO,
bradykinin promotes the appearance of another relaxing
agent, consistent with an EDHF, when they are both
curtailed. Significantly, the latter phenomenon is seen
regardless of whether NO inhibition is obtained with
L-NAME treatment or after eNOS deletion. The mechanism
whereby this latent relaxing agent is uncovered by the
combined removal of NO and CO is still to be defined.
However, a distinct possibility, based on current knowledge
(Nishikawa et al., 2000; Yaghi et al., 2004), is that NO and CO
normally exert a braking effect on an EDHF originating from
a cytochrome P450-based reaction. Indeed, the ductus is
endowed with several cytochrome P450 species (F Coceani,
unpublished data), including the 2J species that has been
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Figure 4 Mouse ductus arteriosus. Prenatal patency and time
course of closure in WT vs NOS-deleted animals. For each group, the
number of experiments is given above the columns, and a significant
difference (Po0.05; ANOVA) between WT and eNOS/ fetuses is
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linked to EDHF through its ability to catalyze the conversion
of arachidonic acid in to vasorelaxant epoxides (Capdevila
et al., 2002; Yaghi et al., 2004). Further work will be required
to validate this scheme.
Two final points deserve a comment and they relate to the
inhibition exerted by TRAM-34/apamin on the bradykinin-
induced relaxation of certain eNOS/ preparations, even
in the absence of a concomitant ZnPP treatment and the
reason for the paradoxical enlargement of the ductus in the
eNOS/ fetus in utero. The former occurrence is reminis-
cent of findings in the adult vasculature (Scotland et al.,
2005; Fe´le´tou and Vanhoutte, 2006), where interference with
PGE2 and NO synthesis may be sufficient to unfold the EDHF
mechanism. Perhaps, in accord with our proposed scheme,
in these particular preparations, the CO mechanism was not
efficient enough to curtail EDHF. Alternatively, the finding
may reflect the multiplicity of agents, unlikely all to be
under NO/CO control, potentially accounting for EDHF
activity (Fe´le´tou and Vanhoutte, 2006). Equally puzzling is
the ‘overdilatation’ of the ductus in the eNOS/ fetus.
A structural change can be ruled out since the vessel was
actually smaller in the mutant compared to the WT when
removed from the animal (see Table 1). In all likelihood, this
condition denotes an active process being sustained by
relaxant(s) that may be local and/or blood-borne. PGE2 is
one such compound and, accordingly, the ductus enlarge-
ment was reversed by treating the mother with indometha-
cin. It is significant, however, that the ductus remained
patent even when combining PGE2 inhibition with eNOS
deletion. This observation reasserts the concept that patency
is sustained by a host of agents, including CO and EDHF in
addition to PGE2 and NO, ensuring collectively a remarkable
degree of synergy and reciprocal compensation.
In conclusion, we have shown that NO, modulating the
tone of the ductus arteriosus, originates primarily from
eNOS. Its absence, however, does not result in narrowing of
the vessel in vivo, thus implying a function of alternative
relaxant(s). PGE2, in particular, is preferentially linked with
NO in a mutual process of compensation. CO is also assigned
a role in tone regulation and, in fact, its relaxing influence
on the ductus appears to match that of PGE2. In the latter
respect, the mouse differs from the lamb where the CO
system is ineffective in the resting vessel. In addition, a
complex relationship exists between NO and CO whereby
the former agent may condition the formation and the
action of the latter both at rest and in response to
bradykinin. Suppression of NO and CO formation along
with PGE2 results in the appearance of EDHF, which
consequently qualifies itself as a potential compensatory
mechanism with an early development in gestation. Collec-
tively, these findings underline the importance of preserving
ductus patency for fetal homeostasis, with several agents,
whether latent or normally operational, contributing in a
cooperative fashion to this process.
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